<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050773</url>
  </required_header>
  <id_info>
    <org_study_id>MEDSCI20210407</org_study_id>
    <nct_id>NCT05050773</nct_id>
  </id_info>
  <brief_title>Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)</brief_title>
  <official_title>A Real-world Study of Clinical Characteristics, Treatment Patterns and Effectiveness in Chinese Patients With Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Life oasis public service center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a multi-center, prospective, cohort study based on registration of Chinese&#xD;
      angina pectoris patients. After signing the informed consent, all patients will be screened&#xD;
      as per the inclusion and exclusion criteria. Estimated 1500 eligible patients will be&#xD;
      enrolled. Two natural cohort will be formed according to whether Nicorandil will be&#xD;
      prescribed to patients or not. The baseline information of patients will be recorded and&#xD;
      patients will be followed up to observe the effectiveness of different anti-angina regimens.&#xD;
      Follow-up visits will be conducted at Month 3, 6, 9, 12 after enrollment. The visits at&#xD;
      Months 3, 6 and 9 will be conducted in the form of electronic patient reported outcomes&#xD;
      (ePRO) + telephone follow-up, and the visit at Month 12 will be conducted on site. Patients&#xD;
      are required to fill in the patient diary records (weekly) during the course of the study.&#xD;
&#xD;
      This study is designed to establish a cohort of Chinese angina pectoris patients and compare&#xD;
      the effectiveness of different anti-angina regimens in patients with angina pectoris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After having signed informed consent (Day 0), the patients will be screened for enrollment.&#xD;
      About 1500 eligible patients will be enrolled in this study. The basic information of&#xD;
      eligible patients including demographic characteristics, history of present illness, past&#xD;
      history, Rose questionnaire, vital sign, medication information, SAQ and other optional&#xD;
      examination data will be collected at Day 0. At Day 0, the patients will join the study&#xD;
      Wechat Mini Program developed for online follow up and patient education by scan the QR code&#xD;
      provided by investigators. After enrollment, the following information will be collected by&#xD;
      ePRO with WeChat Mini Program or telephone follow up of month 3, 6 and 9: vital sign,&#xD;
      medication information, SAQ, AE. The follow up of month 12 will be conducted on site which&#xD;
      will collect SAQ, AE and other optional examination data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>SAQ-SS change at Month 12</measure>
    <time_frame>at Month 12</time_frame>
    <description>Change in Seattle Angina Questionnaire (SAQ) summary score at Month 12 from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAQ-SS change at Month 3, 6 and 9</measure>
    <time_frame>at Month 3, 6 and 9</time_frame>
    <description>Changes in Seattle Angina Questionnaire (SAQ) summary score at Months 3, 6, and 9 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular stenosis degree change at Month 12</measure>
    <time_frame>at Month 12</time_frame>
    <description>Changes in retest results of vascular stenosis imaging at Month 12 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>12 Month</time_frame>
    <description>Medication compliance evaluated by proportion of days covered (PDC)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1556</enrollment>
  <condition>Angina Pectoris</condition>
  <condition>Real World Study</condition>
  <arm_group>
    <arm_group_label>Nicorandil group</arm_group_label>
    <description>Patients who are prescribed with Nicorandil with or without other concomitant medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Nicorandil group</arm_group_label>
    <description>Patients who are prescribed with antianginal drugs except Nicorandil</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        angina pectoris patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        1. Patients with angina pectoris who have evidence of coronary angiography or coronary&#xD;
        computed tomography angiography (CTA) performed within 1 year and meet any of the following&#xD;
        requirements:&#xD;
&#xD;
          1. Imaging examination shows ≥ 50% stenosis and with typical or atypical angina symptoms;&#xD;
&#xD;
          2. Imaging examination shows &lt; 50% stenosis; with typical or similar angina symptoms, and&#xD;
             the treadmill exercise test or stress echocardiography or radionuclide stress test&#xD;
             results are positive;&#xD;
&#xD;
          3. Post-PCI stenosis of left vessels is ≥ 50%; 2. Currently taking or judged by the&#xD;
             physicians as suitable to taking at least one oral antianginal drug (e.g.,&#xD;
             beta-blockers, nitrates, calcium antagonists and potassium channel openers); 3. Have&#xD;
             basic reading and writing abilities, and can correctly fill in the Seattle Angina&#xD;
             Questionnaire(SAQ) after being trained by the investigator; 4. Able to use smart&#xD;
             phones; 5. Voluntarily participate in the study and sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have been diagnosed with malignant tumors that seriously threaten survival and have&#xD;
             expected survival time of less than 1 year;&#xD;
&#xD;
          2. Have participated in other clinical studies within the past 1 month;&#xD;
&#xD;
          3. With poor compliance or with other conditions unsuitable for this study as assessed by&#xD;
             physicians.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Zeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anzhen hospital, Capital medical university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiliang Zhao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Anzhen hospital, Capital medical university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Zeng, MD</last_name>
    <phone>13301373114</phone>
    <email>yzeng_anzhen@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiliang Zhao, MD</last_name>
    <phone>15901030129</phone>
    <email>dellzhaoxiliang@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiliang Zhao, MD</last_name>
      <phone>15901030129</phone>
      <email>dellzhaoxiliang@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Changping District Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liling Sun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Daxing District People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zichuan Tong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Miyun District Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qihua Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yong Zeng</investigator_full_name>
    <investigator_title>Professor and Director, First Ward of Coronary Heart Disease Center</investigator_title>
  </responsible_party>
  <keyword>Angina Pectoris</keyword>
  <keyword>Real World Study</keyword>
  <keyword>Nicorandil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

